The US FDA approved Axonics’ r-SNM sacral neuromodulation system for treating overactive bladder and urinary retention on 14 November. The agency approved the same device for treating chronic fecal incontinence on 9 September. Axonics expects r-SNM to rival Medtronic's InterStim II non-rechargeable sacral neuromodulation system, but Medtronic claims the r-SNM technology infringes on Medtronic’s intellectual property.
Axonics Modulation Technologies Inc. is fighting Medtronic PLC in both the incontinence-treatment device market and in the courtroom.
Axonics’ rechargeable sacral neuromodulation (r-SNM) system competes with Medtronic’s InterStim and InterStim II sacral neurostimulation systems, which are indicated for treating urinary retention, overactive bladder and chronic fecal incontinence in...